Hepatitis Monthly

Published by: Kowsar

The Effect of Octreotide on Urine Output During Orthotopic Liver Transplantation and Early Postoperative Renal Function; A Randomized, Double-Blind, Placebo-Controlled Trial

Mohammad Ali Sahmeddini 1 , * , Afshin Amini 1 and Nima Naderi 1
Authors Information
1 Shiraz Anesthesiology and Intensive Care Research Center, Shiraz University of Medical Science, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: September 2013, 13 (9); e12787
  • Published Online: September 18, 2013
  • Article Type: Research Article
  • Received: June 10, 2013
  • Revised: July 31, 2013
  • Accepted: August 21, 2013
  • DOI: 10.5812/hepatmon.12787

To Cite: Sahmeddini M A, Amini A, Naderi N. The Effect of Octreotide on Urine Output During Orthotopic Liver Transplantation and Early Postoperative Renal Function; A Randomized, Double-Blind, Placebo-Controlled Trial, Hepat Mon. 2013 ;13(9):e12787. doi: 10.5812/hepatmon.12787.

Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Junge G, Schewior LV, Kohler S, Neuhaus R, Langrehr JM, Tullius S, et al. Acute renal failure after liver transplantation: incidence, etiology, therapy, and outcome. Transplant Proc. 2006; 38(3): 723-4[DOI][PubMed]
  • 2. O'Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant. 2007; 7(1): 168-76[DOI][PubMed]
  • 3. Steadman RH, Csete M. Complications of liver transplantation. Seminars in Anesthesia, Perioperative Medicine and Pain. 1996; 15(3): 250-5[DOI]
  • 4. Lewandowska L, Matuszkiewicz-Rowinska J. Acute kidney injury after procedures of orthotopic liver transplantation. Ann Transplant. 2011; 16(2): 103-8[PubMed]
  • 5. Rueggeberg A, Boehm S, Napieralski F, Mueller AR, Neuhaus P, Falke KJ, et al. Development of a risk stratification model for predicting acute renal failure in orthotopic liver transplantation recipients. Anaesthesia. 2008; 63(11): 1174-80[DOI][PubMed]
  • 6. Fonseca-Neto OCLD, Miranda LEC, Melo PS, Sabat BD, Amorim AG, Lacerda CM. Predictors of acute kidney injury in patients undergoing a conventional orthotopic liver transplant without veno-venous bypass. ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo). 2011; 24(2): 152-158
  • 7. Lima EQ, Zanetta DM, Castro I, Massarollo PC, Mies S, Machado MM, et al. Risk factors for development of acute renal failure after liver transplantation. Ren Fail. 2003; 25(4): 553-60[PubMed]
  • 8. Steadman RH. Anesthesia for liver transplant surgery. Anesthesiol Clin North America. 2004; 22(4): 687-711[DOI][PubMed]
  • 9. Mandell MS, Katz JJ, Wachs M, Gill E, Kam I. Circulatory pathophysiology and options in hemodynamic management during adult liver transplantation. Liver Transplantation and Surgery. 1997; 3(4): 379-387[DOI]
  • 10. Planinsic RM, Lebowitz JJ. Renal failure in end-stage liver disease and liver transplantation. Int Anesthesiol Clin. 2006; 44(3): 35-49[DOI][PubMed]
  • 11. Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol. 2007; 13(42): 5552-9[PubMed]
  • 12. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009; 361(13): 1279-90[DOI][PubMed]
  • 13. Schrier RW, Shchekochikhin D, Ginès P. Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. Nephrol Dial Transpl 2012; 27(7): 2625-8
  • 14. Arroyo V. Review article: hepatorenal syndrome--how to assess response to treatment and nonpharmacological therapy. Aliment Pharmacol Ther. 2004; 20 Suppl 3: 49-54[DOI][PubMed]
  • 15. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999; 29(6): 1690-7[DOI][PubMed]
  • 16. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010; 51(2): 576-84[DOI][PubMed]
  • 17. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008; 48 Suppl 1-103[DOI][PubMed]
  • 18. Cardenas A, Arroyo V. Renal and circulatory dysfunction in liver cirrhosis. Pathogenesis and treatment. Ann Gastroenterol 2007; 14(3)
  • 19. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004; 40(1): 55-64[DOI][PubMed]
  • 20. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant. 2005; 20(9): 1813-20[DOI][PubMed]
  • 21. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 2003; 38(1): 238-43[DOI][PubMed]
  • 22. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology. 2001; 120(4): 975-83[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader